DARS2

DARS2 encodes the mitochondrial aspartyl-tRNA synthetase, a homodimeric enzyme that aminoacylates mitochondrial tRNA-Asp and is therefore essential for mitochondrial translation and respiratory chain function (PMID:24606902, PMID:33977142). Loss of DARS2 causes severe, cell-type-specific vulnerability: neurons—particularly Purkinje cells and cortical/hippocampal neurons—undergo progressive mitochondrial dysfunction, neuroinflammation, and cell death, whereas oligodendrocytes tolerate respiratory chain deficiency, explaining the predominantly neuronal pathology in leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation (LBSL), a disease caused by biallelic DARS2 mutations whose severity follows a genotype-dependent continuum extending to axonal Charcot-Marie-Tooth neuropathy (PMID:28985337, PMID:32766765, PMID:22023289, PMID:40814755). Cell-type-specific differences in DARS2 exon 3 splicing efficiency govern the degree of residual functional protein in neural versus non-neural cells, providing a molecular basis for selective CNS vulnerability (PMID:22023289, PMID:37563224). Beyond its canonical mitochondrial aminoacylation role, DARS2 is secreted from epithelial cells in a TNFα/TNFR1-dependent manner and promotes M1-like macrophage polarization, and in cancer cells it drives G1-to-S cell cycle progression via CDK4 upregulation and PINK1-mediated mitophagy (PMID:41214844, PMID:39990673).

1. 2012 High

   Resolving why DARS2 mutations selectively damage the nervous system despite ubiquitous expression, this study showed that cell-type-specific splicing efficiency of DARS2 exon 3 is intrinsically lower in neural cells, so intronic LBSL mutations cause disproportionate exon skipping and protein loss in the most vulnerable tissue.

   Evidence Splicing reporter constructs transfected into neural vs. non-neural cell lines with quantitative RT-PCR readout

   PMID:22023289

   Open questions at the time

   • Trans-acting splicing factors responsible for differential exon 3 inclusion are not identified
   • Splicing was measured in cell lines, not primary human neurons or oligodendrocytes in vivo
2. 2014 High

   Establishing the core enzymatic requirement, conditional Dars2 knockout in heart and skeletal muscle demonstrated that DARS2 is essential for mitochondrial protein synthesis and respiratory chain assembly, and revealed that mitochondrial proteostasis stress signals (e.g., FGF21 induction) are activated independently of respiratory chain deficiency.

   Evidence Conditional cardiac/skeletal muscle Dars2 knockout mice with respiratory chain assays, mitochondrial translation measurements, and FGF21 expression analysis

   PMID:24606902

   Open questions at the time

   • Whether the same proteostasis stress responses occur in neurons was not tested
   • Downstream signaling pathways connecting mitochondrial proteostasis sensing to FGF21 induction were not fully delineated
3. 2017 High

   Demonstrating that neuronal death—not demyelination—is the primary driver of LBSL pathology, cell-type-specific Dars2 ablation showed that forebrain neurons die progressively from mitochondrial dysfunction while oligodendrocytes survive despite equivalent respiratory chain deficiency.

   Evidence CamKII-Cre and oligodendrocyte-Cre conditional Dars2 knockout mice with respiratory chain assays, histopathology, and neuroinflammation markers

   PMID:28985337

   Open questions at the time

   • Molecular basis for oligodendrocyte resistance to DARS2 loss remains unknown
   • Whether secondary demyelination contributes to disease progression independently of neuronal loss is unclear
4. 2019 High

   Extending the neuronal phenotype, Dars2 loss in cortical and hippocampal neurons was shown to cause progressive brain atrophy, corpus callosum thinning, and behavioral deficits, with transcriptomic evidence that microglial neuroinflammation precedes overt neurodegeneration.

   Evidence CamKIIα-Cre conditional Dars2 knockout mice with RNA-seq, behavioral assays, MRI, and microglial morphology analysis

   PMID:31887305

   Open questions at the time

   • Causal contribution of neuroinflammation versus intrinsic neuronal death to disease progression not dissected
   • Whether anti-inflammatory intervention can slow neurodegeneration was not tested
5. 2020 High

   Purkinje cells were shown to be exquisitely dependent on DARS2, with cell-specific deletion causing near-complete Purkinje cell loss by 15 weeks and rapid cerebellar ataxia, consistent with the prominent cerebellar phenotype in LBSL patients.

   Evidence Pcp2-Cre Purkinje cell-specific Dars2 knockout mice with mitochondrial function assays, histopathology, and motor behavioral testing

   PMID:32766765

   Open questions at the time

   • Whether Purkinje cell vulnerability reflects higher mitochondrial translation demand or lower compensatory capacity is unresolved
   • Non-cell-autonomous effects on other cerebellar neurons not characterized
6. 2021 Medium

   Structure–function relationships were established for DARS2: the enzyme functions as a homodimer, and missense variants disrupting tRNA-Asp binding, aminoacyl-adenylate binding, or the dimerization interface abolish mitochondrial function.

   Evidence Structural analysis of variant positions with functional complementation in yeast msd1Δ (oxidative growth assay)

   PMID:33977142

   Open questions at the time

   • No crystal structure of human DARS2 is available; structural inferences are based on homology models
   • Aminoacylation kinetics for individual variants not measured in a purified system
7. 2022 Medium

   Genotype–severity correlations were refined: the p.Glu277Lys variant (affecting dimerization/catalysis) completely ablates function whereas p.Glu158Val (affecting tRNA binding) causes partial loss, demonstrating that different domains contribute unequally to catalytic activity.

   Evidence Yeast msd1Δ complementation with oxidative growth and oxygen consumption measurements plus in silico structural modeling

   PMID:35820270

   Open questions at the time

   • Human DARS2 enzymatic activity for these variants not measured directly
   • Whether partial loss variants permit residual mitochondrial translation in human neurons is untested
8. 2023 Medium

   Patient iPSC-derived cerebral organoids revealed that DARS2 deficiency causes broad mRNA metabolism and splicing dysregulation beyond simple aminoacylation loss, with LBSL neurons showing growth defects, suggesting non-canonical DARS2 roles.

   Evidence SMART-seq2 single-cell RNA-seq of LBSL patient iPSC-derived organoids; live cell imaging of iPSC-derived neurons; exon 3 splicing and protein analysis

   PMID:37563224

   Open questions at the time

   • Whether RNA metabolism changes are direct or secondary to mitochondrial dysfunction is unresolved
   • Non-canonical DARS2 functions have not been biochemically defined
9. 2025 Medium

   Multiple independent advances in 2025 expanded DARS2 biology in three directions: (1) a genotype-severity continuum was demonstrated, with hypomorphic variants causing axonal CMT without leukoencephalopathy; (2) AAV9-mediated DARS2 gene supplementation rescued neuronal mitochondrial function and neurodegeneration in both patient cells and knockout mice; and (3) DARS2 was found to have extramitochondrial functions—as a TNFα-induced secreted factor driving M1 macrophage polarization and as a bladder cancer cell cycle promoter via CDK4/PINK1-mitophagy.

   Evidence Enzymatic activity assays in HEK293 cells and patient fibroblasts (PMID:40814755); AAV9 gene delivery in iPSC neurons and intracerebroventricular injection in Dars2 KO mice (PMID:40948401); airway epithelial cell secretion assays with macrophage polarization readouts (PMID:41214844); siRNA/overexpression in bladder cancer cells with xenograft validation (PMID:39990673)

   PMID:39990673 PMID:40814755 PMID:40948401 PMID:41214844

   Open questions at the time

   • AAV9 gene therapy long-term efficacy and optimal dosing not established
   • Mechanism by which DARS2 exits mitochondria for secretion is not defined
   • CDK4/PINK1-mitophagy link to DARS2 in cancer awaits independent replication
   • Whether the secreted DARS2 paracrine function is relevant in the CNS is unknown

• Key unresolved questions include the molecular basis for differential neuronal versus glial vulnerability to DARS2 loss, whether non-canonical (extra-mitochondrial) DARS2 functions contribute to LBSL pathogenesis, and whether gene therapy can achieve durable clinical benefit in patients.
• No high-resolution structure of human DARS2 is available
• Direct aminoacylation kinetics for disease-associated variants have not been measured with purified human enzyme
• Mechanism connecting DARS2 loss to the mRNA splicing dysregulation observed in organoids is unknown
• Contribution of neuroinflammation as a therapeutic target in LBSL is untested